News
-
-
COMMUNIQUÉ DE PRESSE
Spexis announces extension of moratorium, receipt of an additional payment related to the sale of a preclinical antibiotics program and reversion of the lonodelestat license from Santhera
Spexis AG extends moratorium and receives payment for antibiotics program sale while reverting lonodelestat license from Santhera -
COMMUNIQUÉ DE PRESSE
Kinarus Therapeutics Holding AG publishes FY2023 Financial Statements and announces details on Business Combination with Curatis AG and Reverse Share Split
Kinarus Therapeutics Holding AG releases FY2023 Financial Statements & details on Business Combination with Curatis AG and Reverse Share Split. Postponement of 2023 Annual Report. Reverse Share Split to be implemented on 25 April 2024 -
COMMUNIQUÉ DE PRESSE
R&S Group publishes annual report 2023 with strong sales and record profitability and confirms good start into 2024 with high cash conversion
R&S Group Holding AG reports strong sales and record profitability in the 2023 annual report, starts 2024 positively with high cash conversion and proposes dividend and capital band for growth -
-
COMMUNIQUÉ DE PRESSE
R. STAHL, with significantly improved sales and profitability in 2023, forecasts further sales growth for 2024
R. STAHL reports significant sales and profitability improvement in 2023 with positive outlook for 2024. Detailed financial results and forecasts provided in the Annual Report -
-
-
COMMUNIQUÉ DE PRESSE
Lalique Group announces its 2023 results
Lalique Group announces EUR 179.2 million in operating revenue for 2023, a 5% increase from the previous year. EBIT reaches EUR 7.0 million with a margin of 3.9%. No dividend proposed for 2023. Expecting high single-digit revenue growth in 2024 -
